PATENT CLAIM ANALYSIS

Application Number: 16201481
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["514", "001000"]

Abstract:
The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

Claim (Index 10):
A method of reducing the risk of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), or the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) following hip or knee replacement surgery, in a patient in need of treatment with rivaroxaban and verapamil, comprising:\n (a) administering about 100 to about 480 mg verapamil daily to the patient; and (b) administering a daily dose of 5 mg to 7.5 mg of rivaroxaban to the patient; wherein the patient has a creatinine clearance (CL Cr ) of >50 mL/min to 79 mL/min.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.07407
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12688038', '13184704', '13454255', '13454286', '13092459']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7147927845070876
- 35 USC 102 Novelty (BERT): 0.5158943955480978
- Combined Prediction Score: 0.6949029456111886
- Mean Citation Score: 231.753408
- Max Citation Score: 234.70894
- Similarity Product: 140.0840111453998

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test